Brookline analyst Kemp Dolliver initiated coverage of Candel Therapeutics (CADL) with a Buy rating and $25 price target Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies, the analyst tells investors in a research note. The firm says the company’s lead candidate CAN-2409 met the primary endpoint in a Phase 3 trial in newly-diagnosed localized prostate cancer in intermediate- or high-risk patients, setting the stage for an application filing in Q4 of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics announces addition to multiple Russell Indexes
- Candel Therapeutics assumed with a Buy at H.C. Wainwright
- Candel Therapeutics Announces $15M Stock Offering
- Candel Therapeutics prices 3.2M shares at $4.67 in registered direct offering
- Candel Therapeutics Appoints Charles Schoch as CFO